- Home
- NPWR vs AARD Comparison
NPWR vs AARD Comparison
Compare NPWR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPWR
- AARD
- Stock Information
- Founded
- NPWR 2010
- AARD 2017
- Country
- NPWR United States
- AARD United States
- Employees
- NPWR N/A
- AARD N/A
- Industry
- NPWR Industrial Machinery/Components
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- NPWR Energy
- AARD Health Care
- Exchange
- NPWR Nasdaq
- AARD Nasdaq
- Market Cap
- NPWR 148.7M
- AARD 154.9M
- IPO Year
- NPWR N/A
- AARD 2025
- Fundamental
- Price
- NPWR $2.13
- AARD $10.44
- Analyst Decision
- NPWR Buy
- AARD Strong Buy
- Analyst Count
- NPWR 2
- AARD 4
- Target Price
- NPWR $4.00
- AARD $31.25
- AVG Volume (30 Days)
- NPWR 1.3M
- AARD 50.1K
- Earning Date
- NPWR 05-12-2025
- AARD 05-14-2025
- Dividend Yield
- NPWR N/A
- AARD N/A
- EPS Growth
- NPWR N/A
- AARD N/A
- EPS
- NPWR N/A
- AARD N/A
- Revenue
- NPWR $250,000.00
- AARD N/A
- Revenue This Year
- NPWR $308.00
- AARD N/A
- Revenue Next Year
- NPWR $1,811.08
- AARD N/A
- P/E Ratio
- NPWR N/A
- AARD N/A
- Revenue Growth
- NPWR 100.00
- AARD N/A
- 52 Week Low
- NPWR $1.48
- AARD $4.88
- 52 Week High
- NPWR $14.28
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- NPWR 55.27
- AARD N/A
- Support Level
- NPWR $1.48
- AARD N/A
- Resistance Level
- NPWR $1.75
- AARD N/A
- Average True Range (ATR)
- NPWR 0.24
- AARD 0.00
- MACD
- NPWR 0.10
- AARD 0.00
- Stochastic Oscillator
- NPWR 56.52
- AARD 0.00
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.